As of the end of fiscal year 2024, Tracenable has captured detailed data on Sartorius Stedim Biotech's corporate ownership structure, providing a comprehensive view of its downstream entities and the role within the broader group hierarchy.a
The dataset includes information on 64 affiliated entities, encompassing subsidiaries, joint ventures, associates, and other related companies in which Sartorius Stedim Biotech holds an equity interest or exercises control as the ultimate parent.a
Tracenable's data also records effective ownership percentages that Sartorius Stedim Biotech holds across these entities, providing transparency into its corporate control, ownership hierarchy, and group governance practices.a
| Entity Name | Country | Type | Ownership | LEI | PermID |
|---|---|---|---|---|---|
ACCESSIA PHARMA S.A.a | BEL | Subsidiary | 100% | 0000000 | 0000000 |
XpressBioX SRLa | BEL | Subsidiary | 100% | 0000000 | 0000000 |
XPRESS BIOLOGICS S.A.a | BEL | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius Stedim Belgium S.A.a | BEL | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius Stedim Nordic oya | FIN | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius Xell GmbHa | DEU | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius CellGenix GmbHa | DEU | Subsidiary | 76% | 0000000 | 0000000 |
Sartorius Stedim Biotech GmbHa | DEU | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius Stedim Plastics GmbHa | DEU | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius Stedim North America Holding GmbHa | DEU | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius Stedim Systems GmbHa | DEU | Subsidiary | 100% | 0000000 | 0000000 |
Sartorius Stedim Cellca GmbHa | DEU | Subsidiary | 100% | 0000000 | 0000000 |
| 0000000 | 0000000 | 0000000 | 0000000 | 0000000 | 0000000 |
| 0000000 | 0000000 | 0000000 | 0000000 | 0000000 | 0000000 |
| Showing 12 out of 64 entities. Get complete coverage in the full dataset. | |||||
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sartorius Stedim Biotech’s data sources below and access millions more through our Disclosure Search.
Tracenable's dataset provides geographic insights into Sartorius Stedim Biotech's group entities, revealing where its subsidiaries, joint ventures, associates, and affiliates are located worldwide.a
In total, the Sartorius Stedim Biotech group consists of 64 entities distributed across 30 countries, reflecting the company's global footprint and jurisdictional presence.a
This visualization highlights the geographical distribution of Sartorius Stedim Biotech's corporate structure, helping assess its international exposure, operational reach, and cross-border governance landscape.a
In 2024, Tracenable identified that the Sartorius Stedim Biotech group consisted of 64 entities operating across 30 countries.a
This indicates a high geographic diversification, reflecting Sartorius Stedim Biotech's expansion strategy, global footprint, and cross-border exposure.a
Sartorius Stedim Biotech's subsidiaries and affiliates are primarily concentrated in Europe and Asia, which host 84.38% of its total entities.a
This regional distribution suggests that Sartorius Stedim Biotech's operational and financial activities are centered in these markets, either due to core business operations, supply chain proximity, or favorable regulatory environments.
Sartorius Stedim Biotech shows a moderate to high level of transparency regarding its ownership structure.
The disclosure includes information on subsidiaries, joint ventures, and associates, allowing partial visibility into the company's downstream relationships and areas of shared control.a
While not a full edge-level disclosure, the data still provides meaningful insight into Sartorius Stedim Biotech's governance framework and group composition, positioning it among more transparent reporters in its industry.
No. Tracenable's data does not indicate any entities registered in jurisdictions typically categorized as low-tax or offshore financial centers, suggesting that Sartorius Stedim Biotech's ownership network is primarily domiciled in standard corporate jurisdictions or that Sartorius Stedim Biotech does not provide full transparency on its corporate structure.a